Author

Michael A. Stashko

University of North Carolina at Chapel Hill

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Molecular Biology· 2 Neuroscience· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 1 Approach:statistical model· 1

Frequent Co-Authors

Kenneth H. PearceiD· 3 shared Stephen V. FryeiD· 3 shared C.H. ArrowsmithiD· 2 shared Devan J. ShelliD· 2 shared Fengling LiiD· 2 shared Jacqueline L. Norris-DrouiniD· 2 shared Lindsey Ingerman JamesiD· 2 shared Mélanie UgueniD· 2 shared

Activity by Year

2022-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMolecular Biology

Kenneth H. PearceORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Design, synthesis and cellular characterization of a new class of IPMK kinase inhibitors

Yubai Zhou, Pratima Chapagain, Desmarini Desmarini, Dilipkumar Uredi, Michael A. Stashko, Hundaol Huluka, Lucia E. Rameh, Julianne T. Djordjevic, Raymond D. Blind, Xiaodong Wang

This study designs, synthesizes, and characterizes a new class of IPMK kinase inhibitors, showing reduced glioblastoma cell growth and a novel InsP5 metabolic signature.

Journal of Medicinal Chemistry · Jul 25, 2025Peer-reviewedPharmacology & Toxicology

Potent and Selective SETDB1 Covalent Negative Allosteric Modulator Reduces Methyltransferase Activity in Cells

Mélanie Uguen, Devan J. Shell, Madhushika Silva, Yu Deng, Fengling Li, Magdalena M. Szewczyk, Ka Yang, Yani Zhao, Michael A. Stashko, Jacqueline L. Norris-Drouin, Jarod M. Waybright, Serap Beldar, Justin M. Rectenwald, Angie L. Mordant, Thomas S. Webb, , Stephen V. Frye

The paper identifies UNC10013, a covalent ligand targeting SETDB1's 3TD domain, which reduces methyltransferase activity and shows selectivity in cells.

Nature Communications · Feb 24, 2025Peer-reviewedMolecular Biology

SETDB1 Triple Tudor Domain Ligand, (R,R)-59, Promotes Methylation of Akt1 in Cells

Mélanie Uguen, Yu Deng, Fengling Li, Devan J. Shell, Jacqueline L. Norris-Drouin, Michael A. Stashko, Suzanne Z. Ackloo, C.H. Arrowsmith, Lindsey Ingerman James, Pengda Liu, Kenneth H. Pearce, Stephen V. Frye

The paper shows that (R,R)-59, a SETDB1 ligand, enhances SETDB1-mediated methylation of Akt1 and promotes cell proliferation.

ACS Chemical Biology · Aug 9, 2023Peer-reviewedMolecular Biology

AD Informer Set: Chemical tools to facilitate Alzheimer's disease drug discovery

Frances Potjewyd, Joel K. Annor‐Gyamfi, Jeffrey Aubé, Shaoyou Chu, Ivie L. Conlon, Kevin J. Frankowski, Shiva Krishna Reddy Guduru, Brian P. Hardy, Megan D. Hopkins, Chizuru Kinoshita, Dmitri Kireev, Emily R. Mason, Charles Travis Moerk, Felix O. Nwogbo, Kenneth H. Pearce, , Alison Donnelly Axtman

The paper compiles an annotated set of 171 small molecule modulators targeting 98 novel AD therapeutic proteins, serving as chemical tools for hypothesis validation.

Alzheimer s & Dementia Translational Research & Clinical Interventions · Jan 1, 2022Peer-reviewedNeuroscience